3 results
Objectives:To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose. The secondary objective is to…
This study is an open-label, non-randomized extension to study CCDZ173X2201. It aims to provide treatment with CDZ173 to patients withAPDS/PASLI who participated in study CCDZ173X2201 or who were treated previously with PI3Kδ inhibitors other than…
Part BPrimary:• To determine the anti-tumor activity of NM21 1480 according to RECIST 1.1• To assess the safety and tolerability of NM21 1480 in patients with selected advanced cancers treated at or around the recommended Phase 2 dose (RP2D)• To…